Paying for future success in gene therapy

Science

Volumn 352, Issue 6289, 2016, Pages 1059-1061

  Orkin, Stuart H ^a   Reilly, Philip ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b THIRD ROCK VENTURES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS AND CELL COMPONENTS; DRUG; FUTURE PROSPECT; GENETIC ANALYSIS; TECHNOLOGICAL DEVELOPMENT;

ARTICLE; DRUG MANUFACTURE; GENE THERAPY; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ANEMIA, SICKLE CELL; CYSTIC FIBROSIS; ECONOMICS; FORECASTING; GAUCHER DISEASE; HEMOPHILIA A; TREATMENT OUTCOME; TRENDS;

EUROPE; UNITED STATES;

ANEMIA, SICKLE CELL; CYSTIC FIBROSIS; FORECASTING; GAUCHER DISEASE; GENETIC THERAPY; HEALTH CARE COSTS; HEMOPHILIA A; HUMANS; TREATMENT OUTCOME;

EID: 84973360045     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf4770     Document Type: Article

References (20)

1. T. Friedmann, R. Roblin, Science 175, 949 (1972).
2. S. H. Orkin, A. G. Motulsky, Orkin-Motulsky Report: Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (NIH, Bethesda, MD, 1995); http://bit.ly/InvestGeneTher.
3. S. Hacein-Bey-Abina et al., N. Engl. J. Med. 371, 1407 (2014).
4. A. Aiuti et al., Science 341, 1233151 (2013).
5. A. C. Nathwani et al., N. Engl. J. Med. 371, 1994 (2014).
6. J. W. Bainbridge et al., N. Engl. J. Med. 372, 1887 (2015).
7. F. Simonelli et al., Mol. Ther. 18, 643 (2010).
8. M. Cavazzana-Calvo et al., Nature 467, 318 (2010).
9. A. Biffi et al., Science 341, 1233158 (2013).
10. J. Kaiser, Science 335, 645 (2012).
11. T. A. Burrow, R. J. Hopkin, N. D. Leslie, B. T. Tinkle, G. A. Grabowski, Curr. Opin. Pediatr. 19, 628 (2007).
12. B. M. Feldman et al., Haemophilia 18, 680 (2012).
13. T. L. Kauf, T. D. Coates, L. Huazhi, N. Mody-Patel, A. G. Hartzema, Am. J. Hematol. 84, 323 (2009).
14. L. M. Bryant et al., Hum. Gene Ther. Clin. Dev. 24, 55 (2013).
15. National Foundation for Transplants, FAQ (2016); https:// bit-ly/TransplantCosts.
16. C. Y. Johnson, Washington Post, 9 March 2016; http:// wapo.st/1NrJ15K.
17. The National Institute for Health and Care Excellence; https://NICE.org.uk/.
18. P. Bonanas, Ed., "NICE rebuffs Vertex's Orkambi," in BioCentury Extra, 22 March 2016.
19. E. Schoonveld, Re-pricing rules in Japan slash prices for "huge sales" drugs (2016); https://bit.ly/27x5BAL.
20. F. Sloan, C.-R. Hsieh, Health Economics (MIT Press, Cambridge, MA, 2012).